Peripheral Blood Mononuclear Cells (Type 1 Diabetes)

Description

LeukoPAC-D-PBMC – Disease-State Cryopreserved Peripheral Blood Mononuclear Cells

LeukoPAC-D-PBMC delivers cryopreserved peripheral blood mononuclear cells from donors with documented disease conditions, collected under IRB-approved protocols. Disease-state PBMCs are essential for cell therapy development because manufacturing processes and assays optimized using healthy donor cells frequently fail to translate to cells from patients in the target population.

T1D donor PBMCs reflect the persistent islet autoimmunity and Treg dysregulation characteristic of patients with ongoing or prior beta-cell destruction.

Why Disease-State PBMCs

Patients eligible for cell therapies have often been treated with multiple rounds of chemotherapy or other interventions, which can compromise T cell functionality and shift cellular phenotypes in ways that healthy donor controls do not capture. Process development on disease-state PBMCs allows manufacturing teams and assay developers to validate workflows against material that reflects the immune biology of the patient population they intend to treat.

Available Indications

This product is sourced from donors with documented type 1 diabetes (T1D). OrganaBio’s disease-state donor pool spans 24 autoimmune and chronic inflammatory indications including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, Crohn’s disease, ulcerative colitis, psoriasis, and others. Contact the scientific team to confirm availability and lot status for your specific indication.

Documentation

Each sample is supported by comprehensive documentation including disease history, treatment background, inclusion and exclusion criteria compliance, and demographic profiles. Every lot ships with a Certificate of Analysis. Donors are enrolled under IRB-approved protocols with verified clinical diagnosis.

Configuration

Standard configuration: 1.0×10⁷ cells per vial, cryopreserved, stored at <−150°C in liquid nitrogen vapor phase. Custom cell counts, fresh format, and specific donor criteria available on request. Cells are for preclinical research use only and not for use in humans.

For background on disease-state donor samples in cell therapy development, see Why Disease-State Donor Samples Are Essential for Cell Therapy Development.

{“@context”:”https://schema.org”,”@type”:”Product”,”name”:”LeukoPAC-D-PBMC – Type 1 Diabetes Disease-State Cryopreserved PBMCs”,”description”:”Cryopreserved peripheral blood mononuclear cells from donors with documented type 1 diabetes (T1D). Collected under IRB-approved protocols. Used for islet autoimmunity research, Treg modulation studies, and beta-cell antigen-specific T cell assays.”,”brand”:{“@type”:”Brand”,”name”:”OrganaBio”},”manufacturer”:{“@type”:”Organization”,”name”:”OrganaBio”,”url”:”https://www.organabio.com”},”category”:”Disease-State Donor Material”,”sku”:”D-PBMC-T1D-050″,”image”:”https://www.organabio.com/wp-content/uploads/2026/05/organabio-leukopac-d-pbmc-2026.png”,”offers”:{“@type”:”Offer”,”availability”:”https://schema.org/InStock”,”url”:”https://www.organabio.com/product/leukopak-d-pbmc-t1d/”,”seller”:{“@type”:”Organization”,”name”:”OrganaBio”}}}

{“@context”:”https://schema.org”,”@type”:”FAQPage”,”@id”:”https://www.organabio.com/product/leukopak-d-pbmc-t1d/#faq”,”mainEntity”:[{“@type”:”Question”,”name”:”What are Type 1 Diabetes PBMCs used for?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”PBMCs from T1D donors are used for GAD65 and insulin peptide-specific T cell assays, regulatory T cell frequency and function studies, anti-CD3 therapy mechanism-of-action work, and islet autoimmunity biomarker discovery.”}},{“@type”:”Question”,”name”:”What viability can I expect for cryopreserved Type 1 Diabetes PBMCs?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”OrganaBio targets greater than 80% post-thaw viability for disease-state PBMCs. Lot-specific viability data is included in the Certificate of Analysis.”}},{“@type”:”Question”,”name”:”Are Type 1 Diabetes PBMC donors recallable?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Yes. OrganaBio maintains a recallable donor pool. Donors can be re-collected for longitudinal studies. Availability is indication-dependent.”}},{“@type”:”Question”,”name”:”What HLA and KIR typing is provided?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”High-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, and DP is performed on every donor. KIR genotyping is included as standard.”}},{“@type”:”Question”,”name”:”Are Type 1 Diabetes PBMCs research use only or available at cGMP grade?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Disease-state material is research/discovery use only (RUO). For autoimmune cell therapy GMP starting material, the clinical process uses the patient’s own apheresis.”}}]}